The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients with Type 1 Diabetes
Saxagliptin
MAGE at 24 weeks
NCT01559025
Evaluation of Vildagliptin (Galvus®) as add‐on to Insulin in Residual β‐cell Function and Inflammatory Markers in New‐onset Type 1 Diabetes Mellitus
Vildagliptin
MMTT C‐peptide at 3, 6, 9 and 12 month
NCT02442544
Effect of Prebiotic Fibre on Gut Microbiota, Intestinal Permeability and Glycaemic Control in Children with Type 1 Diabetes: A Pilot Randomized, Double Blind, Placebo Controlled Study
Prebiotic 1:1 oligofructose:inulin
HbA1C at 3 months
NCT02820558
A Phase I Study of Safety and Pharmacological Activity of Substance P in the Reversal of Recent‐Onset Type 1 Diabetes
Substance P
Safety at 20–27 days
NCT02505893
A Monocentric, Open‐label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients with New‐onset Type 1 Diabetes
ATG + pG‐CSF + rapamycin + human pancreatic islet
Safety and MMTT C‐peptide at 12 months
NCT02940418
Use of Stem Cells in Diabetes Mellitus Type 1
AD‐MSCs + BM‐MNCs
Safety at 6 months
NCT02293837
EXTEND
Tocilizumab
MMTT C‐peptide at 12 months
NCT02617654
A Randomized, Double‐blinded Placebo‐controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP‐1 Receptor Agonist Liraglutide on Β‐cell Function in C‐peptide Positive Type 1 Diabetic Patients
Liraglutide
MMTT C‐peptide at 12 months
NCT03170544
A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK‐1092 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
MK‐1092
Safety and maximal glucose infusion rate at 33 days
NCT02814838
A Phase 2, Multicentre, Randomized, Double‐blind, Placebo‐controlled Study in Patients with New‐onset Type 1 Diabetes
Ladarixin
MMTT C‐peptide at 13±1 weeks
NCT02411253
DIABIL‐2
rhIL‐2
MMTT C‐peptide at 12 months
NCT02803892
MONORAPA
Rapamycin /+ Vildagliptin
MMTT C‐peptide at 4±1, 12±2 weeks
NCT02218619
Clinical Investigation of Efficacy of Tauroursodeoxycholic Acid (TUDCA) to Enhance Pancreatic Β‐cell Survival in Type 1 Diabetes by Reducing Endoplasmic Reticulum Stress
Tauroursodeoxycholic Acid (TUDCA)
MMTT C‐peptide at 6, 12, and 18 months
NCT03272269
A Phase I Placebo‐controlled, Double‐blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY‐0098 in Patients With Recent Onset Type 1 Diabetes
IMCY‐0098
Safety at 24 weeks
NCT03032354
Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta‐cell Function in Children With Newly Diagnosed Type 1 Diabetes ‐ a Randomized Controlled Trial
Probiotics
MMTT C‐peptide at 6 and 12 months
NCT02644759
Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus
aLD‐SCs/CB‐MSCs + G‐CSF
Insulin requirement at 1 month
NCT02354911
A Randomized, Double‐Blind, Placebo‐Controlled, Cross‐Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes
Immunoregulatory Dendritic Cells
MMTT C‐peptide at 12 and 24 months
NCT02624804
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
Stem Cell Educator Therapy
Safety at 12 months
NCT02846545
T1GER
Golimumab
MMTT C‐peptide at 12 months
NCT03011021
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
UCB ‐ Tregs + Liraglutide
Safety at 24 months
NCT02932826
Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg Cells on Autoimmune Diabetes
UCB ‐ Tregs
Safety at 24 months
NCT02384889
Targeting Polyamines Using DFMO in Persons with Type 1 Diabetes: A Randomized, Double‐Masked, Placebo‐Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses
Difluoromethylornithine
Safety with dose escalation at 6 months
NCT03046927
Vitamin D and Residual Beta‐Cell Function in Type 1 Diabetes
Ergocalciferol
MMTT C‐peptide at 12 months
NCT01773707
CTLA4‐Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At ‐Risk for Type 1
Abatacept
Abnormal glucose tolerance
NCT03298542
A Phase 1b Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre‐Symptomatic Type 1 Diabetes
Golimumab
Safety at 26, 52, and 78 weeks
NCT03182426
Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus
Primary outcome
